Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences27 Dec 2019
Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy.
Astellas Pharma and Xyphos Biosciences have announced that Astellas has acquired Xyphos. With the acquisition Astellas will gain Xyphos' novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform, as well as industry-leading immuno-oncology talent, to develop new and potentially better ways to mobilize, target and control immune cells to find, modulate and destroy targeted cells throughout the body.
"At Astellas, immuno-oncology is a primary focus of our R&D strategy, and we are working on the development of next-generation cancer immuno-therapy using new modalities/technologies," said Kenji Yasukawa, President and CEO, Astellas. "The innovative technology in development at Xyphos fits perfectly in advancing our immuno-oncology strategy to create and deliver value for patients. Combining this technology with our capabilities in cell therapy that we have been working on so far, we can create next-generation high-function cells and maximize the value of our technology. We look forward to working with Xyphos' superb team to advance and expand their clinical development programs to bring their novel therapeutics to patients."
"At Xyphos, we are driven to advance our innovative cell therapy technology platform as an exciting new approach to potentially manage and cure cancer," said James Knighton, CEO, Xyphos. "Astellas' commitment to immuno-oncology makes them an ideal partner to advance our proprietary NKG2D-based NK-cell and T-cell platform to the next stage of clinical exploration. Further, we look forward to becoming part of Astellas to accelerate this immuno-oncology research and development in the vibrant South San Francisco community."
Xyphos has developed a flexible and versatile synthetic biology platform to direct cells of the immune system to target single or multiple tumour antigens while controlling the immune cell proliferation and endurance. Xyphos's proprietary molecules can be delivered to natural immune cells or to engineered Chimeric Antigen Receptor (CAR) cells to generate immunotherapies for oncology. Xyphos' patented CAR technology is based on an engineered modification to a natural human receptor named NKG2D. NKG2D exists on natural killer (NK) cells and some T-cells. The designed modification of NKG2D renders it inert, that is, unable to bind to any of its natural ligands, which occur on stressed cells. Through further protein engineering, several natural ligands of NKG2D have been modified to bind exclusively to the otherwise inert NKG2D receptor. Various functional molecules (for example, antibodies that recognize specific tumour antigens) are attached to the modified ligand. The ligand-directed functional molecules then bind exclusively to immune cells expressing the inert CAR on their surface – the proprietary convertibleCAR-cells. The CAR-cells can be directed by the ligand-bound antibody to seek, become activated and attacks a targeted cancer cell. Xyphos' first convertibleCAR-T cell product candidate is in preclinical development and scheduled to be tested in a first-in-human clinical study in 2021.
Considering the acquisition, $120 million was paid upon closing of the acquisition, and Xyphos became a wholly owned subsidiary of Astellas. In addition to this payment and potential future development milestone payments, it will provide a total transaction value of $ 665 million.
FDA orders ranitidine withdrawal due to nitrosamine contamination risk
2 Apr 2020
US drug regulator, the Food and Drug Administration has ordered the immediate withdrawal of all prescription and over-the-counter versions of heartburn drug, ranitidine – commonly known as Zantac – after concluding certain products may present an incre...Read more
UPDATED: COVID-19 PHARMA TRACKER
2 Apr 2020
The latest coronavirus updates and developments impacting the global pharmaceutical supply chain…Read more
China focused on meeting international API demand amid pandemic, say officials
1 Apr 2020
China is stepping up its efforts to produce and ship active pharmaceutical ingredients (APIs), with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease, according to Chinese officials Tuesday.Read more
New blood test able to detect 50 cancer types
31 Mar 2020
Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.Read more
Cambrex names Troy Player as head of early stage development and testing
31 Mar 2020
Cambrex has appointed pharma industry veteran, Troy Player, as president, early stage development and testing, the contract development and manufacturing organisation said Tuesday.Read more
CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility
31 Mar 2020
The Ritedose Corporation, a contract development and manufacturing organisation (CDMO) with a focus on inhalation and ophthalmic products, has partnered with ChargePoint Technology to ensure the sterility of its drug substance mixing process.Read more
EMA to only issue electronic medicines certificates during COVID-19 pandemic
30 Mar 2020
The European Medicines Agency (EMA) said Monday it will only issue electronically signed and authenticated certificates for human and veterinary medicines in place of printed ones so it can continue to provide the documents during the COVID-19 pandemic...Read more
PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?
30 Mar 2020
Joint venture between Spinview and VR Media Technology creates device that provides accurate and fast detection of infectious people with far greater clarity than any single parameter test available today.Read more
New device offers a convenient way to monitor compressed air for viable particles
30 Mar 2020
Specialist cleanroom microbiology solutions company offers the new SAS Super Pinocchio CR compressed air sampling device.Read more
CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown
25 Mar 2020
Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation